Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Announces Quarterly Earnings Results

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) issued its quarterly earnings data on Friday. The company reported $0.45 EPS for the quarter, FiscalAI reports.

Calidi Biotherapeutics Stock Down 3.8%

Shares of NYSEAMERICAN:CLDI opened at $0.27 on Friday. Calidi Biotherapeutics has a 52-week low of $0.26 and a 52-week high of $19.20. The firm has a market capitalization of $2.00 million, a P/E ratio of -0.04 and a beta of 1.11. The stock has a 50 day moving average price of $0.70 and a 200-day moving average price of $1.18. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.12 and a current ratio of 2.12.

Institutional Investors Weigh In On Calidi Biotherapeutics

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after purchasing an additional 12,334 shares during the period. Warberg Asset Management LLC purchased a new position in Calidi Biotherapeutics during the third quarter valued at $28,000. Virtu Financial LLC bought a new stake in shares of Calidi Biotherapeutics during the 4th quarter valued at $25,000. Finally, DRW Securities LLC bought a new stake in shares of Calidi Biotherapeutics during the 4th quarter valued at $173,000. 12.53% of the stock is currently owned by institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.